Article Text

Download PDFPDF
Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In women with an increased risk of breast cancer, does tamoxifen reduce the risk of breast cancer and what are the associated harms?


Randomised (allocation concealed*), blinded {clinicians, patients, data collectors, outcome assessors},* placebo controlled trial with median follow up of 50 months.


Europe, Australia, and New Zealand.


7152 women 35–70 years of age (mean age 51 y, 49% postmenopausal) who had an increased risk of breast cancer. Exclusion criteria included previous invasive cancer, previous deep vein thrombosis or pulmonary embolism, anticoagulant use, and pregnancy. Follow up was 99.8%.


Women were allocated to receive …

View Full Text


  • Sources of funding: Cancer Research UK, and National Health and Medical Research Council Australia.

  • For correspondence: Professor J Cuzick, IBIS Trials Centre, London, UK. Jack.Cuzick{at}

  • * See glossary.

  • Information provided by author.